-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
-
Summary
-
Aerovate Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2020 to 2024.
- Aerovate Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending March 31, 2024 was $4.2 M, a 76.2% increase year-over-year.
- Aerovate Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending March 31, 2024 was $13.7 M, a 101% increase year-over-year.
- Aerovate Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $11.9 M, a 117% increase from 2022.
- Aerovate Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $5.48 M, a 168% increase from 2021.
- Aerovate Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $2.04 M, a 3422% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)